Mexico
· Delayed Price · Currency is MXN Recursion Pharmaceuticals Statistics
Total Valuation
BMV:RXRX has a market cap or net worth of MXN 37.08 billion. The enterprise value is 29.08 billion.
| Market Cap | 37.08B |
| Enterprise Value | 29.08B |
Important Dates
The next estimated earnings date is Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 399.66M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +44.28% |
| Shares Change (QoQ) | +19.86% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 388.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 30.34 |
| PB Ratio | 1.94 |
| P/TBV Ratio | 4.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.47 |
| EV / Sales | 24.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.58 |
Financial Position
The company has a current ratio of 4.11, with a Debt / Equity ratio of 0.10.
| Current Ratio | 4.11 |
| Quick Ratio | 3.85 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.23 |
| Interest Coverage | -278.66 |
Financial Efficiency
Return on equity (ROE) is -86.10% and return on invested capital (ROIC) is -48.52%.
| Return on Equity (ROE) | -86.10% |
| Return on Assets (ROA) | -38.51% |
| Return on Invested Capital (ROIC) | -48.52% |
| Return on Capital Employed (ROCE) | -49.35% |
| Revenue Per Employee | 1.53M |
| Profits Per Employee | -14.68M |
| Employee Count | 800 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 898 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.79 |
Income Statement
In the last 12 months, BMV:RXRX had revenue of MXN 1.22 billion and -11.75 billion in losses. Loss per share was -37.19.
| Revenue | 1.22B |
| Gross Profit | -7.62B |
| Operating Income | -11.73B |
| Pretax Income | -11.76B |
| Net Income | -11.75B |
| EBITDA | -10.74B |
| EBIT | -11.73B |
| Loss Per Share | -37.19 |
Balance Sheet
The company has 10.23 billion in cash and 1.90 billion in debt, giving a net cash position of 8.33 billion.
| Cash & Cash Equivalents | 10.23B |
| Total Debt | 1.90B |
| Net Cash | 8.33B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 19.09B |
| Book Value Per Share | 46.97 |
| Working Capital | 9.04B |
Cash Flow
In the last 12 months, operating cash flow was -7.95 billion and capital expenditures -181.37 million, giving a free cash flow of -8.13 billion.
| Operating Cash Flow | -7.95B |
| Capital Expenditures | -181.37M |
| Free Cash Flow | -8.13B |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -960.08% |
| Pretax Margin | -962.17% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BMV:RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.28% |
| Shareholder Yield | -44.28% |
| Earnings Yield | -31.68% |
| FCF Yield | -21.92% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMV:RXRX has an Altman Z-Score of 0.86. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.86 |
| Piotroski F-Score | n/a |